dihydrostreptomycin 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| antibiotics, produced by Streptomyces strains | 890 | 128-46-1 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
A semi-synthetic aminoglycoside antibiotic that is used in the treatment of TUBERCULOSIS.
|
Drug dosage:
None
ADMET properties:
None
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| None | FDA |
FDA Adverse Event Reporting System (Female)
None
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
None
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | S01AA15 | SENSORY ORGANS OPHTHALMOLOGICALS ANTIINFECTIVES Antibiotics |
| MeSH PA | D000900 | Anti-Bacterial Agents |
| MeSH PA | D000890 | Anti-Infective Agents |
Drug Use | Suggest Off label Use Form| |View source of the data|
None
🐶 Veterinary Drug Use
| Species | Use | Relation |
|---|---|---|
| Cattle | Leptospirosis caused by Leptospira pomona | Indication |
| Dogs | Leptospirosis caused by Leptospira canicola | Indication |
| Dogs | Leptospirosis caused by L Icterohemorrhagiae | Indication |
| Dogs | Leptospirosis caused by Leptospira pomona | Indication |
| Horses | Leptospirosis caused by Leptospira canicola | Indication |
| Horses | Leptospirosis caused by L Icterohemorrhagiae | Indication |
| Horses | Leptospirosis caused by Leptospira pomona | Indication |
| Swine | Leptospirosis caused by Leptospira pomona | Indication |
| Swine | Leptospirosis caused by L grippotyphosa | Indication |
🐶 Veterinary products
| Product | Applicant | Ingredients |
|---|---|---|
| Quartermaster Suspension | HQ Specialty Pharma Corp. | 2 |
| Dry-Mast | HQ Specialty Pharma Corp. | 2 |
| Pfizer-Strep | Zoetis Inc. | 1 |
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 12.26 | acidic |
| pKa2 | 12.92 | acidic |
| pKa3 | 13.62 | acidic |
| pKa4 | 11.91 | Basic |
| pKa5 | 11.21 | Basic |
| pKa6 | 6.48 | Basic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
None
External reference:
| ID | Source |
|---|---|
| N0000168466 | NUI |
| D02512 | KEGG_DRUG |
| 5490-27-7 | SECONDARY_CAS_RN |
| 1549540 | RXNORM |
| C0012317 | UMLSCUI |
| CHEBI:38291 | CHEBI |
| 71R | PDB_CHEM_ID |
| CHEMBL1950576 | ChEMBL_ID |
| CHEMBL3188576 | ChEMBL_ID |
| D004096 | MESH_DESCRIPTOR_UI |
| DB11512 | DRUGBANK_ID |
| 12163 | IUPHAR_LIGAND_ID |
| 1574 | INN_ID |
| P2I6R8W6UA | UNII |
| 439369 | PUBCHEM_CID |
| 002771 | NDDF |
| 004896 | NDDF |
| 111118003 | SNOMEDCT_US |
| 409323004 | SNOMEDCT_US |
| 96028004 | SNOMEDCT_US |
Pharmaceutical products:
None